For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Lpath, Inc.

Calculating rank

USPTO Granted Patents = 23

% Expired Patents = 100.0

EPO Patents = 10

Forward Citations = 50

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Roger A Sabbadini (22 out of 36 patents)

William A Garland (17 out of 38 patents)

Genevieve Hansen (13 out of 17 patents)

4. Steven Tarran Jones (7 out of 14 patents)

5. David Gareth Williams (7 out of 11 patents)

6. Glenn L Stoller (3 out of 3 patents)

7. Rosalia Matteo (2 out of 2 patents)

8. Scott R Pancoast (2 out of 2 patents)

9. Marina Safonov (2 out of 2 patents)

10. James Stephen Swaney (2 out of 2 patents)

11. Jonathan Michael Wojciak (2 out of 2 patents)

12. Gordon B Mills (1 out of 23 patents)

13. James Leigh Hsu (1 out of 1 patent)

14. Tom Huxford (1 out of 1 patent)

15. Amy L Cavalli (1 out of 1 patent)

23 patents: Sort by Forward Citations

1. 9274130 - Prevention and treatment of pain using antibodies to lysophosphatidic acid (2016-03-01),

2. 9274129 - Methods and reagents for detecting bioactive lipids (2016-03-01),

3. 9217749 - Immune-derived moieties reactive against lysophosphatidic acid (2015-12-22),

4. 9181331 - Pharmaceutical compositions for binding sphingosine-1-phosphate (2015-11-10),

5. 9163091 - Compositions and methods for binding lysophosphatidic acid (2015-10-20),

6. 9102718 - Anti-S1P antibody treatment of patients with ocular disease (2015-08-11),

7. 8871202 - Prevention and treatment of pain using antibodies to sphingosine-1-phosphate (2014-10-28),

8. 8796429 - Bioactive lipid derivatives, and methods of making and using same (2014-08-05),

9. 8614103 - Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions (2013-12-24),

10. 8604172 - Humanized antibody compositions and methods for binding lysophosphatidic acid (2013-12-10),

11. 8444970 - Compositions and methods for treating ocular diseases and conditions (2013-05-21),

12. 8401799 - Antibody design using anti-lipid antibody crystal structures (2013-03-19),

13. 8361465 - Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents (2013-01-29),

14. 8222373 - Humanized antibodies and compositions for binding sphingosine-1-phosphate (2012-07-17),

15. 8158124 - Compositions and methods for binding lysophosphatidic acid (2012-04-17),

Company Overview

Lpath, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative therapeutic solutions. The company focuses on lipid-based therapeutics, particularly in the areas of ophthalmology and neurodegenerative diseases. Lpath leverages its proprietary technology platform to create drug candidates that target specific biological pathways, aiming to address unmet medical needs. Through its research and development efforts, Lpath is committed to advancing the field of medicine with novel treatments.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

23 Patents

#263 in San Diego, CA

#3,424 in California

#14,450 in US

#27,736 in the World

San Diego, CA, United States of America

Lpath, Inc.

Forward Citations = 50

15 inventors:

Roger A Sabbadini (22 out of 36 patents)

William A Garland (17 out of 38 patents)

Genevieve Hansen (13 out of 17 patents)

4. Steven Tarran Jones (7 out of 14 patents)

5. David Gareth Williams (7 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lpath, Inc.. Retrieved from https://idiyas.com/company/lpath

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…